Enhanced immune recovery with B/F/TAF compared with DTG/3TC in HIV patients: A prospective observational study
Open Access
- 19 November 2025
- journal article
- research article
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 19 (2) , 103055
Abstract
No abstract availableKeywords
Funding Information
- Jiangsu Commission of Health (Ym2023079)
- Natural Science Foundation of Nantong Municipality (MS2023077)
This publication has 31 references indexed in Scilit:
- Liver function tests, CD4+ counts, and viral load among people living with HIV on dolutegravir compared to efavirenz-based cART; a comparative cross-sectional studyHeliyon, 2024
- Metabolic Consequences of Antiretroviral TherapyCurrent HIV/AIDS Reports, 2022
- HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistanceInternational Journal of Antimicrobial Agents, 2021
- Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated ReviewClinical Pharmacokinetics, 2020
- Dolutegravir-associated hyperglycaemia in patients with HIVThe Lancet HIV, 2020
- Optimizing Treatment for Adults with HIV/AIDS in China: Successes over Two Decades and Remaining ChallengesCurrent HIV/AIDS Reports, 2020
- Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trialThe Lancet HIV, 2019
- Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 InfectionDrugs, 2018
- Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trialThe Lancet, 2017
- Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trialThe Lancet, 2017